Anesthetic Agents Isoflurane and Propofol Decrease Maximal Ca^{2+} -Activated Force and Thus Contractility in the Failing Myocardium[§]

Tao Meng,¹ Xianfeng Ren,¹ Xinzhong Chen, Jingui Yu, Jacopo Agrimi, Nazareno Paolocci, and Wei Dong Gao

Department of Anesthesiology, Qilu Hospital of Shandong University, Jinan, Shangdong, China (T.M., J.Y.); Department of Anesthesiology, China-Japan Friendship Hospital, Beijing, China (X.R.); Department of Cardiac Surgery, Tongji University Medical Center, Wuhan, China (X.C.); Division of Cardiology (J.A., N.P.) and Department of Anesthesiology and Critical Care Medicine (W.D.G.), Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; and Department of Biomedical Sciences, University of Padova, Padova, Italy (N.P.)

Received May 3, 2019; accepted September 11, 2019

ABSTRACT

In the normal heart, frequently used anesthetics such as isoflurane and propofol can reduce inotropy. However, the impact of these agents on the failing myocardium is unclear. Here, we examined whether and how isoflurane and propofol influence cardiac contractility in intact cardiac muscles from rats treated with monocrotaline to induce heart failure. We measured force and intracellular Ca^{2+} ($[\text{Ca}^{2+}]_i$) in trabeculae from the right ventricles of the rats in the absence or presence of propofol or isoflurane. At low to moderate concentrations, both propofol and isoflurane dose-dependently depressed cardiac force generation in failing trabeculae without altering $[\text{Ca}^{2+}]_i$. At high doses, propofol (but not isoflurane) also decreased amplitude of $[\text{Ca}^{2+}]_i$ transients. During steady-state activation, both propofol and isoflurane impaired maximal Ca^{2+} -activated force (F_{max}) while increasing the amount of $[\text{Ca}^{2+}]_i$ required for 50% of maximal activation (Ca_{50}). These events occurred without apparent change in the Hill coefficient, suggesting

no impairment of cooperativity. Exposing these same muscles to the anesthetics after fiber skinning resulted in a similar decrement in F_{max} and rise in Ca_{50} but no change in the myofibrillar ATPase- Ca^{2+} relationship. Thus, our study demonstrates that challenging the failing myocardium with commonly used anesthetic agents such as propofol and isoflurane leads to reduced force development as a result of lowered myofilament responsiveness to Ca^{2+} .

SIGNIFICANCE STATEMENT

Commonly used anesthetics such as isoflurane and propofol can impair myocardial contractility in subjects with heart failure by lowering myofilament responsiveness to Ca^{2+} . High doses of propofol can also reduce the overall amplitude of the intracellular Ca^{2+} transient. These findings may have important implications for the safety and quality of intra- and perioperative care of patients with heart failure and other cardiac disorders.

Introduction

Since the very first demonstration made by Dr. William T. Morton at the Massachusetts General Hospital in October 1846, general anesthesia has become an inseparable part of patient procedures (both surgical and nonsurgical). However, it is increasingly evident that anesthetics may have a wide array of off-pathway (side) effects, especially in patients with severe disease conditions and comorbidities (Martin, 2005; Reich et al., 2005; Armstrong et al., 2017; Kawasaki

et al., 2018; Juhász et al., 2019). For anesthesiologists, of particular concern are patients with heart failure (HF) (Smit-Fun and Buhre, 2016). In the last few decades, the number of procedures that have become amenable to individuals with moderately depressed heart function has increased (Benjamin et al., 2017). Some common procedures may include cardiac-related operations, such as implantation of ventricular assist devices, pacemakers, synchronized stimulators, and defibrillators, and noncardiac procedures from hip replacement to endoscopies. However, recent clinical studies have shown that the perioperative mortality and morbidity in HF patients remain high (Flu et al., 2010; Mebazaa et al., 2010), as much as 2- to 3-fold higher than for patients with coronary artery disease (Hernandez et al., 2004; Hammill et al., 2008). These high rates of morbidity and mortality result from complications such as heart attack, worsening of HF, and other organ failure (Lee et al., 1999; Poldermans et al., 2009).

This study was supported by grants from the Shangdong Provincial Natural Science Foundation [Grant ZR2017BH022] and China Postdoctoral Science Foundation [Grant 2019M652395] to T.M., a grant from the American Heart Association [Grant 17GRNT33670367] to W.D.G., and grants from the National Institutes of Health [Grant R01 HL136918 and R01 HL063030] to N.P.

¹T.M. and X.R. contributed equally to this work.

<https://doi.org/10.1124/jpet.119.259556>

[§] This article has supplemental material available at jpet.aspetjournals.org.

ABBREVIATIONS: $[\text{Ca}^{2+}]_i$, intracellular Ca^{2+} ; Ca_{50} , $[\text{Ca}^{2+}]_i$ required at 50% of F_{max} ; FAC, fractional area of change; F_{max} , maximal Ca^{2+} -activated force; HF, heart failure; K-H, Krebs-Henseleit; MCT, monocrotaline; RV, right ventricular; SR, sarcoplasmic reticulum.

It has been well documented that anesthetic agents affect myocardial contraction in normal myocardium (Bosnjak et al., 1992; Hebbard et al., 1997; Jiang and Julian, 1998; Davies et al., 2000; Sprung et al., 2001; Bovill, 2006). Moreover, we have shown that the inhalational agent isoflurane, at low-to-moderate doses (0.5%–1.5%), reduces myofilament Ca^{2+} responsiveness in normal rat trabeculae without altering intracellular Ca^{2+} levels (Ding et al., 2011). We also demonstrated that propofol jeopardizes force development in healthy rat cardiac muscle via decreased myofilament Ca^{2+} responsiveness (Meng et al., 2016). Furthermore, we have reported that both propofol and isoflurane produce a *direct* effect on myofilament function, and we have identified several potential key targets for these anesthetics within the contractile proteins (Meng et al., 2016). Nevertheless, the impact of anesthetic agents on cardiac force generation in failing preparations remains poorly characterized, particularly from a mechanistic point of view, and is somewhat controversial. Indeed, studies have shown that inhalational agents can depress myocardial contractility in both failing and healthy hearts (Pagel et al., 1996; Preckel et al., 2004). However, other reports suggest that the failing myocardium can be relatively insensitive to inhalational agents (Kissin et al., 1983; Vivien et al., 1997). Of note, in studies that have demonstrated a reduction in cardiac function by anesthetics, the mechanism of impairment has not been clarified.

In the present study, we tested the hypothesis that both isoflurane and propofol (two widely used anesthetic agents) depress force in the failing myocardium, and examined whether the negative inotropic effect stems from a *direct* action of the agents on the myofilaments.

Materials and Methods

Animal Care. A total of 36 LBN/F1 rats of either sex (250–300 g; Harlan Laboratories, Indianapolis, IN) were used in these experiments. Animal care and experimental protocols were approved by the Animal Care and Use Committee of the Johns Hopkins University School of Medicine.

Right Heart Failure in the Rat. Rats received a single intraperitoneal injection of monocrotaline (MCT; 60 mg/kg in saline, MCT group, $n = 20$) or an equivalent volume of saline (control group, $n = 16$). No anesthesia was required given the short duration of injection (<5–10 seconds). They were weighed weekly for 3 weeks post injection and then daily. Animals were also monitored for clinical signs of HF, which included successive days of weight loss, dyspnea, cold extremities, or lethargy. Two rats in the MCT group did not develop right heart failure after injection, and two rats died accidentally. These rats were excluded from the study. The experimental matrix is detailed in Supplemental Table 1.

Cardiac function of the rats was evaluated by echocardiography and hemodynamic measurements. Rats from the two groups were lightly sedated with isoflurane (<1%) before undergoing electrocardiogram analysis and temperature monitoring. Then, right ventricular (RV) function was evaluated by echocardiography (Agilent Sonos 5500, 15-MHz probe, 3-cm depth; Agilent Technologies). RV wall thickness and chamber dimensions were measured at the midlevel parasternal long-axis view and parasternal short-axis view, respectively, at the level of the papillary muscles. RV fractional area of change (FAC) was calculated based on manually traced areas of the right ventricle cavity endocardium at the parasternal long-axis view during systole and diastole (i.e., apical four-chamber view) using the following equation: $\text{FAC} = (\text{end-diastolic area} - \text{end-systolic area}) / \text{end-diastolic area} \times 100\%$. Software associated with the echo machine analyzed the traced areas to derive volumes and calculate the RV ejection fraction.

Cardiac output was calculated based on pulse-Doppler wave velocity wave form across the pulmonary valve (i.e., velocity-time integral) and the cross-sectional area of the pulmonary artery: $\text{cardiac output} = \text{cross-sectional area} \times \text{velocity-time integral} \times \text{heart rate}$.

Determination of Force and Intracellular Ca^{2+} in Intact Trabeculae. When the MCT-injected rats exhibited overt HF, they were anesthetized with an intra-abdominal injection of pentobarbital (100 mg/kg). Then, the heart was exposed by midsternotomy, rapidly excised, and placed in a dissection dish. The aorta was cannulated and the heart perfused in a retrograde fashion with dissecting Krebs-Henseleit (K-H) solution equilibrated with 95% O_2 and 5% CO_2 . The dissecting K-H solution was composed of (in millimolar concentrations) NaCl 120, NaHCO_3 20, KCl 5, MgCl 1.2, glucose 10, CaCl_2 0.5, and 2,3-butanedione monoxime 20 [pH 7.35–7.45 at room temperature (21–22°C)]. Trabecular muscle from the right ventricle of the heart was dissected and mounted between a force transducer and a motor arm, superfused with K-H solution at a rate of ~10 ml/min, and stimulated at 0.5 Hz.

Force was measured by a force transducer system (KG7; Scientific Instruments GmbH, Heidelberg, Germany) and expressed in millinewtons per square millimeter of cross-sectional area. The muscles underwent isometric contractions with the resting muscle length set so that resting force was 15% of total force development (i.e., optimal muscle length). This resting muscle length, which corresponded to a resting sarcomere length of 2.20–2.30 μm as determined by laser diffraction (Gao et al., 1996), was maintained throughout the experiments.

Intracellular Ca^{2+} ($[\text{Ca}^{2+}]_i$) was measured by using the free acid form of fura-2 (Dai et al., 2007; Gao et al., 2012). Fura-2 potassium salt was microinjected iontophoretically into one cell and allowed to spread throughout the whole muscle (via gap junctions) without affecting force development. The tip of the electrode (~0.2 μm in diameter) was filled with fura-2 salt (1 mM), and the remainder of the electrode was filled with 150 mM KCl. After successful impalement into a superficial cell in nonstimulated muscle, a hyperpolarizing current of 5–10 nA was passed continuously for ~15 minutes. In some preparations, multiple injection sites were needed to achieve the desired loading of fura-2 because the duration of each injection was limited to <10 minutes. Fura-2 epifluorescence was measured by excitation at 380 and 340 nm. Fluorescent light was collected at 510 nm by a photomultiplier tube (R1527; Hamamatsu Photonics, Hamamatsu, Japan). The output of the photomultiplier was collected and digitized. $[\text{Ca}^{2+}]_i$ was given by the following equation (after subtraction of the autofluorescence):

$$[\text{Ca}^{2+}]_i = K'_d(R - R_{\min}) / (R_{\max} - R) \quad (1)$$

where R is the observed ratio of fluorescence (340/380 nm), K'_d is the apparent dissociation constant, $R_{\max}$ is the ratio of 340 nm/380 nm at saturating Ca^{2+} concentration, and $R_{\min}$ is the ratio of 340/380 nm at 0 Ca^{2+} concentration. The values of K'_d , $R_{\max}$, and $R_{\min}$ were determined by *in vivo* calibrations as described previously (Gao et al., 1994, 1998).

Ryanodine (1.0 μM) was used to enable steady-state activation. After the muscles were exposed to ryanodine for 15 minutes, different levels of tetanization were induced briefly (~4–8 seconds) by stimulating the muscles at 10 Hz at various concentrations of extracellular Ca^{2+} concentrations (0.5–20 mM). The steady-state force– $[\text{Ca}^{2+}]_i$ relations were fit with a function of the Hill equation:

$$F = F_{\max} [\text{Ca}^{2+}]_i^n / ([\text{Ca}_{50}^n + [\text{Ca}^{2+}]_i^n]) \quad (2)$$

where F is the steady-state force at various $[\text{Ca}^{2+}]_i$, $F_{\max}$ is the maximal Ca^{2+} -activated force, Ca_{50} is the $[\text{Ca}^{2+}]_i$ required to achieve 50% maximal activation, and n is the Hill coefficient.

Chemical Skinning of Trabecular Muscles. After the steady-state experiments, the same trabeculae were immediately skinned by 15–20 minutes of exposure to Triton X-100 (1%) in relaxing solution containing (in millimolar concentrations) KCl 100, HEPES 25,

K₂EGTA 10, creatine phosphate sodium salt (Na₂CrP) 15, Na₂ATP 5, MgCl₂ 5.15, and leupeptin 0.5 (pH 7.2 with KOH). Activating solution contained (in millimolar concentrations) Ca²⁺-EGTA 10, KCl 100, HEPES 25, Na₂CrP 15, Na₂ATP 5, MgCl₂ 4.75, and leupeptin 0.5 (pH 7.2). Different Ca²⁺ concentrations were obtained by mixing the activating solution and relaxing solution in different ratios. The readiness of the skinned preparation was confirmed by the loss of pink color, clear visibility of the sarcomeres, and instantaneous force development upon exposure to activating solutions. Diastolic sarcomere length was determined by direct visualization under 100× magnification and was set at ~2.2 μm. Resting force was usually 10%–15% of maximal activated force at this sarcomere length. Force–Ca²⁺ relations were obtained by exposing the skinned muscles to activating solutions with various extracellular Ca²⁺ concentrations and were fit with the Hill equation:

$$F = F_{\max} [\text{Ca}^{2+}]^n / (\text{Ca}_{50}^n + [\text{Ca}^{2+}]^n) \quad (3)$$

where *F* is the steady-state force at various [Ca²⁺], *F*_{max} is the maximal Ca²⁺-activated force, Ca₅₀ is the [Ca²⁺] required to achieve 50% maximal activation, and *n* is the Hill coefficient.

Determination of Myofibrillar ATPase Activity. Myofibrils were prepared from the failing right ventricle as previously described (Murphy and Solaro, 1990; Dai et al., 2007) with careful use of protease inhibitors. Assays were carried out under incubation conditions established by varying the total concentration of metals, salts, and ligands; ionic strength was maintained by using stability constants compiled by Fabiato (1981). Assays were performed at pH 7.0 with 50 mM imidazole, 50 mM KCl, and 2 mM MgATP. Inorganic phosphate liberation was measured by using a microtiter plate version of the standard assay as described by Rarick et al. (1997). Protein concentration was determined by a variation of the Lowry method (Bio-Rad Laboratories, Hercules, CA). In the final assay conditions, the myofibrillar protein concentration was diluted in buffer to a concentration of 0.2 mg/ml; the protein concentration was determined again for final calculations. Mg-ATPase activity was calculated in nanomoles of inorganic phosphate liberated per milligram of myofibrillar protein per minute.

Preparation of Isoflurane and Propofol. Isoflurane was purchased from Baxter Healthcare Corporation (Deerfield, IL) and dissolved into working solutions as a percentage by isoflurane vaporizer with O₂ as a carrier. The concentrations of isoflurane were expressed as percentages. We checked the concentration of isoflurane in the experimental solution periodically using high-performance liquid chromatography to ensure that the desired concentrations were delivered. Propofol was purchased from Sigma-Aldrich (St. Louis, MO) in powder form and dissolved in DMSO as a stock solution. The final concentration of DMSO at the desired working propofol concentrations was less than 0.1%. In preliminary studies, we determined that this DMSO concentration had no effect on force development or [Ca²⁺]_i transients (data not shown).

Statistical Analysis. We determined the number of samples/experiments based on a probability for $\alpha < 0.05$, a power of 0.80, and an anticipated depression in force development of >20% of baseline or control value with S.E.M. = 6%–8%. Paired *t* test and one-way ANOVA were used for statistical analysis of the data (Systat 10.2.01; Systat Software Inc., San Jose, CA). A value of *P* < 0.05 was considered to indicate statistically significant differences between groups. Unless otherwise indicated, pooled data are expressed as means ± S.E.M.

Results

Both Isoflurane and Propofol Decrease Force Development in Trabecular Muscles from Nonfailing Hearts Without Affecting Amplitude of the [Ca²⁺]_i Transient. We first evaluated the effect of isoflurane and propofol on contraction in isolated trabecular muscles from

the nonfailing hearts of saline-injected rats (Table 1). Figure 1 shows the pooled data of all muscles exposed to isoflurane or propofol. Isoflurane significantly reduced developed force (starting at 1%, *P* < 0.05) but did not alter [Ca²⁺]_i transient amplitudes at the concentrations tested (*P* > 0.05; Fig. 1A). Propofol significantly diminished developed force beginning at 30 μM and reduced [Ca²⁺]_i amplitude when the concentration reached 100 μM (Fig. 1C). The steady-state force–[Ca²⁺]_i relation obtained before and after anesthetic exposure showed that both anesthetics decreased *F*_{max}. With isoflurane, *F*_{max} decreased from 80 ± 6 to 58 ± 5 mN/mm² (*P* < 0.05), and with propofol, *F*_{max} decreased from 84 ± 4.3 to 49.6 ± 4.7 mN/mm² (*P* < 0.05). Both agents increased the Ca₅₀. With isoflurane, Ca₅₀ increased from 0.526 ± 0.038 to 1.213 ± 0.085 μM (*P* < 0.05), whereas with propofol, it increased from 0.56 ± 0.08 to 0.74 ± 0.04 μM (*P* < 0.05; Fig. 1, B and D). Neither isoflurane nor propofol significantly affected the Hill coefficient. This parameter changed from 4.11 ± 0.36 to 2.29 ± 0.19 (*P* < 0.05) after isoflurane treatment and from 4.8 ± 0.37 to 2.98 ± 0.39 after propofol (*P* < 0.05). We did not observe any difference between muscles from either sex. Consistent with previous findings (Ding et al., 2011; Meng et al., 2016), these data suggest that in healthy cardiac muscles, the primary targets of isoflurane and propofol are the myofilaments.

A Single Dose of MCT Induces RV Remodeling and Dysfunction. Next, we sought to determine the effect produced by these two anesthetic agents on intact cardiac muscles from failing rat hearts. To this end, we induced RV failure by administering one dose (60 mg/kg) of MCT intra-abdominally, which has been shown to induce pulmonary hypertension followed by RV hypertrophy and failure (Kögler et al., 2003; Stones et al., 2013). Consistent with these previous findings, here we found that 4 to 5 weeks after MCT injection, rats exhibited signs of RV failure—namely, low food intake, retarded weight gain, and lack of daily activity—as compared with saline-injected rats. Echocardiography revealed markedly decreased RV contractility as indicated by smaller ejection fraction, less FAC, and less cardiac output. The RV was also manifestly dilated (Fig. 2; Table 1), denoting severe RV remodeling. There were no differences in response to MCT injection between male and female rats.

Isoflurane and Propofol Both Reduce Twitch Force but with Differing Effects on [Ca²⁺]_i Transients. Whether isoflurane or propofol alters force development and whole [Ca²⁺]_i transients in isolated (intact) failing trabecular muscle preparations is currently unclear. To fill this gap in knowledge, we administered isoflurane or propofol to intact (RV) trabeculae isolated from MCT-injected rats. Figure 3 shows the typical raw recordings of force and [Ca²⁺]_i transients at different isoflurane concentrations and the pooled data of all muscles tested. Isoflurane weakened force development in a dose-dependent manner without significantly altering [Ca²⁺]_i transient amplitude at any concentration tested (up to 3%). Force was reduced significantly at isoflurane concentrations >1.5%.

At concentrations between 0 and 30 μM, propofol did not significantly alter either developed force or [Ca²⁺]_i; however, at 40 μM and higher, it reduced force development. Only at concentrations above 50 μM did it also significantly decrease [Ca²⁺]_i transient (Fig. 4). In essence, isoflurane decreases force development by decreasing myofilament Ca²⁺

TABLE 1

Cardiac performance indices of right ventricle in control and monocrotaline-injected rats

	Control	Monocrotaline
RV dimensions (mm)		
Basal	2.87 ± 0.24	3.75 ± 0.12*
Middle	2.41 ± 0.22	4.56 ± 0.41*
Apical	1.93 ± 0.32	3.79 ± 0.49*
Long axis	7.84 ± 0.22	10.97 ± 0.4*
Ejection fraction (%)	72.8 ± 6.4	26.12 ± 8.7*
FAC (%)	32.5 ± 2.69	13.8 ± 2.61*
Cardiac output (ml/min)	33 ± 3.67	9.46 ± 1.18*

* $P < 0.01$ vs. control, $n = 12$ in each group.

responsiveness in failing RV muscle. In contrast, propofol has a dual negative effect on Ca^{2+} -dependent cardiac force generation: at low concentrations, the reduction in force stems from changes in myofilament properties (i.e., *decreased myofilament Ca^{2+} responsiveness*), whereas at moderate/high doses, this decrement originates from *decreased Ca^{2+} cycling/availability*.

Effect of Propofol and Isoflurane on Myofilament Ca^{2+} Responsiveness. We next obtained steady-state force- $[\text{Ca}^{2+}]_i$ relationships to *directly* assess the myofilament properties that underlie changes in myofilament Ca^{2+} responsiveness. We determined this relationship in the failing RV muscle before and during anesthetic exposure. At baseline, the steady-state force- $[\text{Ca}^{2+}]_i$ relationship was diminished in failing trabecular muscles as compared with that in nonfailing muscles. Exposure to 1.5% isoflurane also

significantly lowered $F_{\max}$ from 37.89 ± 4.45 to 22.97 ± 2.1 mN/mm^2 ($P < 0.05$ vs. before isoflurane). Yet the Ca_{50} was unchanged (0.65 ± 0.11 and 0.5 ± 0.06 μM , respectively; $P > 0.05$; Fig. 5A; Table 2). Likewise, propofol (50 μM) reduced $F_{\max}$ from 32.47 ± 3.23 to 22.48 ± 1.7 mN/mm^2 ($P < 0.05$) but did not alter Ca_{50} (0.5 ± 0.08 and 0.65 ± 0.1 μM , respectively; $P > 0.05$; Fig. 6A; Table 2). Notably, neither propofol nor isoflurane affected the Hill coefficient (with isoflurane: 2.15 ± 0.26 vs. without isoflurane: 2.81 ± 0.18 , $P > 0.05$; with propofol: 2.5 ± 0.14 vs. without propofol: 4.27 ± 0.12 , $P > 0.05$). This set of data shows that propofol and isoflurane primarily decreased $F_{\max}$ in the intact muscle.

We next determined the steady-state force- $[\text{Ca}^{2+}]_i$ relations in skinned muscles to rule out cytosolic factors that could potentially influence this relationship (Gao et al., 1994). In the presence of isoflurane, $F_{\max}$ was significantly depressed from 44.66 ± 3.21 to 34.32 ± 1.3 mN/mm^2 ($P < 0.05$) in skinned fibers. Ca_{50} was unaffected (1.35 ± 0.15 and 1.55 ± 0.18 μM , respectively; $P > 0.05$; Fig. 5B; Table 2). Similarly, in skinned preparations, propofol (50 μM) markedly reduced $F_{\max}$ from 42.42 ± 3.31 to 33.36 ± 2.02 mN/mm^2 ($P < 0.05$), again without affecting Ca_{50} (1.3 ± 0.15 and 1.56 ± 0.25 μM , pre- and postanesthetic, respectively; $P > 0.05$; Fig. 6; Table 2). These data, indicating that isoflurane- and propofol-induced depression of the steady-state force- Ca^{2+} relation persists in skinned muscles, lend further support to the contention that these agents affect myocardial contraction primarily via a direct effect on the myofilament status.

Neither Propofol nor Isoflurane Alter Myofibrillar Mg-ATPase Activity. Next, we determined the Mg-ATPase

Fig. 1. Effect of isoflurane and propofol on contraction and $[\text{Ca}^{2+}]_i$ transients in normal cardiac muscle. (A) Pooled data of trabecular force development and amplitudes of intracellular Ca^{2+} transients in the presence of different concentrations of isoflurane. Force decreased in a dose-dependent manner as concentrations of isoflurane increased, but amplitudes of $[\text{Ca}^{2+}]_i$ transients remained unchanged ($n = 8$). (B) Steady-state force- $[\text{Ca}^{2+}]_i$ relations in the presence and absence of isoflurane (1.5%) in isolated intact trabecular muscles. The steady-state forces were plotted against amplitudes of $[\text{Ca}^{2+}]_i$ transients, which were grouped into bins of 0.5–1 μM ranges ($n = 6$). (C) Pooled data of trabecular force development and amplitudes of intracellular Ca^{2+} transients in the presence of different concentrations of propofol. Force decreased in a dose-dependent manner as concentrations of propofol increased. Amplitudes of $[\text{Ca}^{2+}]_i$ transients remained unchanged until propofol concentrations reached 100 μM ($n = 8$). (D) Steady-state force-intracellular Ca^{2+} relations in the presence and absence of propofol (50 μM) in isolated intact cardiac trabecular muscles. The steady-state forces were plotted against amplitudes of $[\text{Ca}^{2+}]_i$ transients, which were grouped into bins of 0.5–1 μM ranges ($n = 6$). * $P < 0.05$ vs. baseline, paired t test, temperature = 22°C .

Fig. 2. A representative transthoracic echocardiographic image [short axis transverse view (SAX)] of a rat heart showing a severely enlarged right ventricle with flattening of the ventricular septum (SEP). The image was taken 4.5 weeks after the rat received an intra-abdominal injection of monocrotaline (60 mg/kg). The rat also showed signs of right heart failure at the time of the echocardiograph: inactivity, labored breathing, significant loss of body weight, and enlarged liver. BPM, beats per minute; LV, left ventricle.

activity in isolated myofibrils from failing right ventricles treated with propofol or isoflurane to examine whether the anesthetics also affect the energetics of contraction itself. We observed that the overall maximal ATPase activity was diminished in the failing myocardium (55.18 ± 1.38 nM P_i/mg protein per minute; Fig. 7), consistent with previously reported findings (LeWinter, 2005; Joubert et al., 2008). However, neither propofol nor isoflurane affected the Mg-ATPase-pCa relationship (Fig. 7). In fact, the maximal Ca^{2+} -activated Mg-ATPase was 57.92 ± 3.7 nM P_i/mg protein per minute in the presence of isoflurane and 54.56 ± 1.61 nM P_i/mg protein per minute in the presence of propofol ($P > 0.05$ vs. failing control; Fig. 7). Moreover, the Ca^{2+} concentration in the solution for half maximally activated Mg-ATPase activity was 6.31 ± 0.21 μM for the failing preparation at baseline, and 6.33 ± 0.34 and 6.29 ± 0.31 μM after propofol and isoflurane, respectively ($P > 0.1$). Thus, these anesthetic agents decrease force generation without affecting cross-bridge ATP consumption or energetics.

Discussion

Isoflurane and propofol are widely used agents to induce or maintain anesthesia. Our study reveals that both isoflurane and propofol decrease force development in cardiac muscle isolated from rats with RV failure. Furthermore, we showed that the weakened force generation stems from a decrease in maximal Ca^{2+} -activated force, especially at low-to-moderate doses. Decreased Ca^{2+} availability may also contribute to reducing force development, but only at high propofol concentrations. Finally, our data show that neither propofol nor

isoflurane further reduces myofilament Mg-ATPase activity that is already below normal in the failing RV preparation.

Anesthetics and Myofilaments in the Failing Myocardium. Myocardial contractility is jeopardized not only by Ca^{2+} dysregulation (Lehnart et al., 2009) but also by alterations in the myofilaments themselves (Kass and Solaro, 2006; van der Velden, 2011). For example, altered phosphorylation of troponin and other myofilament proteins can cause changes in myofilament Ca^{2+} responsiveness and thus alter force development in the failing heart/myocardium (Knott et al., 2002; van der Velden et al., 2003; Yuan et al., 2006; Bilchick et al., 2007). Oxidation of tropomyosin and actin are also important contributors to contractile dysfunction after ischemia and/or during overt HF (Canton et al., 2004, 2006; Duncan et al., 2005). As a result of these modifications, the failing myocardium often exhibits decreased myofilament Ca^{2+} responsiveness (i.e., decreased F_{max} and increased Ca_{50}) during steady-state activations (Stull et al., 2004; Dai et al., 2006; Belin et al., 2007; Tan et al., 2009).

Recently, we reported that both isoflurane and propofol decrease force development by directly targeting key residues in myosin heavy chain, actin, and myosin light chain (Meng et al., 2016). Consistent with what is observed in normal cardiac muscles, here we found that isoflurane and propofol also compromise force development in failing RV muscle preparations. Moreover, analysis of the steady-state force- Ca^{2+} relationship revealed some important mechanistic aspects regarding the means by which anesthetics affect force generation in the failing cardiac muscle. First and foremost, both anesthetics reduced F_{max} but not Ca_{50} . Second, the myofilament ATPase-pCa relationship was unaffected by these agents. Third, when delivered at high doses, propofol, but not isoflurane, reduced the $[\text{Ca}^{2+}]_i$ transients. In aggregate, these observations support the notion that propofol and isoflurane alter myofilament properties in failing cardiac muscle preparations.

The fact that the anesthetics were able to depress force development *further* and reduce F_{max} supports our recent finding that anesthetics exert their effects by binding directly to target myofilament proteins (Meng et al., 2016) rather than by acting through post-translational pathways, such as phosphorylation and oxidation. However, our current data show that these baseline changes in the myofilament properties of the failing myocardium affect the interaction of anesthetics with the myofilament proteins. For example, our evidence showing that the overall myofilament Mg-ATPase activity is not altered by anesthetics, unlike what occurs in normal muscle preparations, suggests that in a failing heart, anesthetics likely alter cross-bridge cycling but not the interaction between myosin and actin (i.e., cross-bridge formation). This possibility is in keeping with previous evidence showing that isoflurane does not affect myosin-driven actin mobility or maximum myofilament ATPase activity in isolated myosin/actin preparations (Vivien et al., 2005). Taken together, this evidence suggests that, in an HF preparation, anesthetics are likely to target additional myofilament proteins, such as the regulatory proteins troponin, tropomyosin, and myosin light chain. Therefore, our findings support the need for additional, more in-depth studies that evaluate how the interaction between these anesthetic agents and the myofilament proteins influences the cross-bridge cycling in the failing myocardium.

Anesthetics and $[\text{Ca}^{2+}]_i$ Transient/Cycling in the Failing Myocardium. A well known hallmark of HF is

Fig. 3. Effect of isoflurane on force and $[Ca^{2+}]_i$ transient in failing rat cardiac muscle. (A) Raw recordings of force development (left panel) and corresponding $[Ca^{2+}]_i$ transients (right panel) of a trabecular muscle in the presence of different isoflurane concentrations. The muscle was stimulated at 0.5 Hz in the presence of 1.0 mM external Ca^{2+} at room temperature (22°C). (B) Pooled data of trabecular force development and amplitudes of $[Ca^{2+}]_i$ transients in the presence of different isoflurane concentrations. Force development decreased in a dose-dependent manner as concentrations of isoflurane increased. Force development became significantly less than that at baseline at concentrations greater than 1.5%. Amplitudes of $[Ca^{2+}]_i$ transients remained unchanged at all concentrations tested. Temperature = 22°C; external Ca^{2+} = 1.0 mM; stimulation rate = 0.5 Hz. * $P < 0.001$; $n = 8$.

a decrease in the release of Ca^{2+} from the sarcoplasmic reticulum (SR) (Hasenfuss and Pieske, 2002; Piacentino et al., 2003). Factors that contribute to the defective SR function include dysfunction of SR Ca^{2+} ATPase and reduced

SR Ca^{2+} ATPase levels (Hasenfuss, 1998; Hasenfuss et al., 1999; O'Rourke et al., 1999), phosphorylation of SR ryanodine receptor (Marks et al., 2002), and enhanced expression of the Na-Ca exchanger (Flesch et al., 1996; Ahmed et al., 2000).

Fig. 4. Effect of propofol on force and $[Ca^{2+}]_i$ transient in failing rat cardiac muscle. (A) Raw recordings of force development (left panel) and corresponding $[Ca^{2+}]_i$ transients (right panel) of a trabecular muscle in the presence of different propofol concentrations. The muscle was stimulated at 0.5 Hz in the presence of 1.0 mM external Ca^{2+} at room temperature (22°C). (B) Pooled data of trabecular force development and amplitudes of $[Ca^{2+}]_i$ transients in the presence of different propofol concentrations. Force development decreased in a dose-dependent manner as concentrations of propofol increased. Force development became significantly less than that at baseline at concentrations of 40 μM and higher. Amplitudes of $[Ca^{2+}]_i$ transients remained unchanged at all concentrations tested. Temperature = 22°C; external Ca^{2+} = 1.0 mM; stimulation rate = 0.5 Hz. * $P < 0.001$; $n = 8$.

Fig. 5. Steady-state force- $[Ca^{2+}]_i$ relations in the presence and absence of isoflurane (1.5%) in isolated intact and skinned failing trabecular muscles. The steady-state forces were plotted against amplitudes of $[Ca^{2+}]_i$ transients, which were grouped into 0.5- μ M bins. (A) In intact trabeculae, F_{max} was significantly reduced and Ca_{50} was significantly increased by isoflurane. (B) The same muscles in which steady-state relations were first obtained were chemically skinned and activated with various Ca^{2+} concentrations. The effect of isoflurane on F_{max} and Ca_{50} persisted in these skinned muscles. Temperature = 22°C; $n = 6$.

Here we observed that, at concentrations of 50 μ M and above, propofol decreased intracellular transients, an effect that would account for the observed reduction in force development (Fig. 4). However, previous studies that have examined the impact of propofol on myocardial function have generated conflicting results. Early studies that used failing human trabecular muscles from atria and ventricles showed that propofol decreased force development and inhibited isolated SR Ca^{2+} uptake at high concentrations ($\geq 56 \mu$ M) (Sprung et al., 2001). In the normal myocardium, propofol can increase Ca^{2+} -activated ATPase activity, suggesting an increase in myofilament Ca^{2+} sensitivity (Kanaya et al., 2003). However, some of these previous investigations did not evaluate the possible influence of propofol on myofilament sensitivity. *In fact, these studies were carried out without measuring force.* Recently, we re-examined this issue by conducting experiments in which we determined force, sarcomere length, and intracellular cytosolic free Ca^{2+} simultaneously in intact cardiac trabecular muscles (Ding et al., 2011; Meng et al., 2016). We found that propofol lowered force development by decreasing myofilament Ca^{2+} responsiveness. In the present study, we found that high-dose propofol further decreased $[Ca^{2+}]_i$ transients in failing RV muscle preparations, consistent with earlier findings obtained in failing human muscles, which showed that propofol (56 μ M) decreased SR Ca^{2+} uptake (Sprung et al., 2001). Thus, propofol has dual adverse effects on cardiac excitation coupling in the failing myocardium: it decreases myofilament Ca^{2+} responsiveness at low-to-moderate concentrations and SR Ca^{2+} release at high concentrations.

Limitations and Perspective. The previously described functional experiments were carried out at room temperature, not at body temperature. Measuring $[Ca^{2+}]_i$ with our

technique is extremely difficult at 37°C mainly because metabolism of fura-2 is extremely rapid at that temperature. Additionally, obtaining the steady-state force- $[Ca^{2+}]_i$ relationship is virtually impossible at 37°C because SR cycling becomes too rapid. However, we have determined twitch force and corresponding $[Ca^{2+}]_i$ at 37°C in the past and found similar effects by both agents on force and $[Ca^{2+}]_i$ transients (Ding et al., 2011). Nevertheless, we would like to caution readers when drawing conclusions from results obtained at room temperature. Another caveat is that the anesthetic concentrations needed to observe the functional effects were slightly higher than those used clinically. For example, the blood concentration of propofol at which 50% of patients did not respond to skin incision was 18 μ M in the presence of fentanyl (as opposed to 81 μ M without fentanyl), and the concentration at which 95% of patients did not respond to skin incision was 28.9 μ M in the presence of fentanyl as determined by high-performance liquid chromatography (Smith et al., 1994). For isoflurane, the blood concentration at which patients opened their eyes is 0.53% as determined by gas chromatography (Kato et al., 1992). In the current paper, as well as in our prior studies (Ding et al., 2011; Meng et al., 2016), our effective propofol dose range was between 20 and 50 μ M, and effective concentration of isoflurane was 1%–1.5%. We used 50 μ M propofol and 1.5% of isoflurane for most of the experiments. However, this apparent discrepancy has technical and biologic explanations. First, the *in vitro* preparation is superfused rather than coronary perfused; second, the use of room temperature may reduce the efficacy of the drug; third, myocytes are, in general, more sensitive to any given drug at body temperature than they are at room temperature. Thus, future, in-depth studies are needed to evaluate the molecular mechanism that underlies the anesthetic-induced reduction of

TABLE 2

Parameters for force- Ca^{2+} relationships in intact and skinned failing cardiac trabecular muscles

Group	Intact			Skinned		
	F_{max}	Ca_{50}	n	F_{max}	Ca_{50}	n
Isoflurane						
Before	37.89 $\pm$ 4.45	0.65 $\pm$ 0.11	2.15 $\pm$ 0.26	44.66 $\pm$ 3.21	1.35 $\pm$ 0.18	3.0 $\pm$ 0.23
After	22.97 $\pm$ 2.1*	0.50 $\pm$ 0.06	2.81 $\pm$ 0.18	34.32 $\pm$ 1.3*	1.55 $\pm$ 0.14	2.5 $\pm$ 0.18
Propofol						
Before	32.47 $\pm$ 3.23	0.5 $\pm$ 0.08	4.27 $\pm$ 0.12	42.42 $\pm$ 3.31	1.3 $\pm$ 0.15	3.12 $\pm$ 0.54
After	22.48 $\pm$ 1.7†	0.65 $\pm$ 0.1	2.5 $\pm$ 0.14	33.36 $\pm$ 2.02†	1.56 $\pm$ 0.25	2.15 $\pm$ 0.12

n, Hill coefficient.

* $P < 0.05$ vs. before isoflurane, $n = 6$.

† $P < 0.05$ vs. before propofol, $n = 6$.

Fig. 6. Steady-state force– $[Ca^{2+}]_i$ relations in the presence and absence of propofol (50 μM) in isolated intact and skinned failing trabecular muscles. The steady-state forces were plotted against amplitudes of $[Ca^{2+}]_i$ transients, which were grouped into 0.5- μM bins. (A) In intact trabeculae, F_{max} was significantly reduced and Ca_{50} was significantly increased by propofol. (B) The same muscles in which steady-state relations were first obtained were chemically skinned and activated with various Ca^{2+} concentrations. The effect of propofol on F_{max} and Ca_{50} persisted in these skinned muscles. Temperature = 22°C; $n = 6$.

myofilament Ca^{2+} responsiveness in the failing myocardium. Recently, we carried out molecular docking studies based on proteomic data obtained in myofilaments treated with photo-labeled anesthetics and have identified several anesthetic binding sites in myosin and actin (Meng et al., 2016). Thus, based on acquired and current evidence, it is tempting to speculate that these anesthetic agents do not directly interfere with the modalities of interaction between myosin and actin. Instead, in HF cardiac muscle preparations, they are more likely to affect regulatory proteins such as troponins, tropomyosin, and myosin-binding protein C. Identifying the binding sites for anesthetics in the regulatory myofilament proteins is fertile terrain for future investigation. Future studies are also warranted to determine possible synergistic effects when the two anesthetic agents are used in combination.

Translationally speaking, the results from this rat pulmonary hypertension–induced (right) HF model will stimulate future in-depth clinical investigation into the effect of anesthetics on the dysfunctional right heart during pulmonary hypertension. Clinically, it has been recognized that anesthetic agents may further depress myocardial function, especially of the right heart, in patients with pulmonary hypertension (McGlothlin et al., 2012). However, this clinically relevant aspect needs to be investigated further, both

in terms of the real magnitude of the anesthetic-imparted RV dysfunction and the effect on clinical outcome in patients with pulmonary hypertension/RV dysfunction requiring anesthesia.

Conclusion. At low-to-moderate concentrations, anesthetics such as isoflurane and propofol reduce force development in failing cardiac muscle preparation by decreasing myofilament Ca^{2+} responsiveness. At high dosage, propofol, but not isoflurane, decreases force development by reducing intracellular Ca^{2+} availability. Our findings that anesthetics exert a negative inotropic effect teach us to exercise caution when delivering anesthesia to patients with HF or other cardiac diseases. Moreover, these data suggest that we make some selective choices among available anesthetics in patients with reduced cardiac performance. Ideally, these findings could create some interest for designing additional anesthetic agents devoid of this adverse effect on myofilament Ca^{2+} responsiveness and SR cycling, or in which these collateral effects are minimized.

Authorship Contributions

Participated in research design: Meng, Ren, Yu, Paolucci, Gao.

Conducted experiments: Meng, Ren, Chen, Gao.

Performed data analysis: Meng, Ren, Chen, Agrimi, Gao.

Wrote or contributed to the writing of the manuscript: Meng, Ren, Yu, Agrimi, Paolucci, Gao.

References

- Ahmed GU, Dong PH, Song G, Ball NA, Xu Y, Walsh RA, and Chiamvimonvat N (2000) Changes in Ca^{2+} cycling proteins underlie cardiac action potential prolongation in a pressure-overloaded Guinea pig model with cardiac hypertrophy and failure. *Circ Res* 86:558–570.
- Armstrong R, Xu F, Arora A, Rasic N, and Syed NI (2017) General anesthetics and cytotoxicity: possible implications for brain health. *Drug Chem Toxicol* 40:241–249.
- Belin RJ, Sumandea MP, Allen EJ, Schoenfeldt K, Wang H, Solaro RJ, and de Tombe PP (2007) Augmented protein kinase C- α -induced myofilament protein phosphorylation contributes to myofilament dysfunction in experimental congestive heart failure. *Circ Res* 101:195–204.
- Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2017) Heart disease and stroke statistics-2017 update: a report from the American Heart Association [published correction appears in *Circulation* (2017) 135:e646; *Circulation* (2017) 136:e196]. *Circulation* 135:e146–e603.
- Bilchick KC, Duncan JG, Ravi R, Takimoto E, Champion HC, Gao WD, Stull LB, Kass DA, and Murphy AM (2007) Heart failure-associated alterations in troponin I phosphorylation impair ventricular relaxation-afterload and force-frequency responses and systolic function. *Am J Physiol Heart Circ Physiol* 292:H318–H325.
- Bovill JG (2006) Intravenous anesthesia for the patient with left ventricular dysfunction. *Semin Cardiothorac Vasc Anesth* 10:43–48.
- Canton M, Neverova I, Menabò R, Van Eyk J, and Di Lisa F (2004) Evidence of myofibrillar protein oxidation induced by postischemic reperfusion in isolated rat hearts. *Am J Physiol Heart Circ Physiol* 286:H870–H877.

Fig. 7. Effect of isoflurane and propofol on myofibrillar Mg-ATPase activity. Isolated myofibrils from failing right ventricles were treated with either isoflurane (1.5%, $n = 5$) or propofol (50 μM , $n = 5$) for 20 minutes. Neither the maximal Ca^{2+} -activated Mg-ATPase activity nor the Ca^{2+} required for half maximal Mg-ATPase activity was affected by the anesthetics.

- Canton M, Skyschally A, Menabò R, Boengler K, Gres P, Schulz R, Haude M, Erbel R, Di Lisa F, and Heusch G (2006) Oxidative modification of tropomyosin and myocardial dysfunction following coronary microembolization. *Eur Heart J* **27**:875–881.
- Dai T, Ramirez-Correa G, and Gao WD (2006) Apelin increases contractility in failing cardiac muscle. *Eur J Pharmacol* **553**:222–228.
- Dai T, Tian Y, Tocchetti CG, Katori T, Murphy AM, Kass DA, Paolucci N, and Gao WD (2007) Nitroxyl increases force development in rat cardiac muscle. *J Physiol* **580**:951–960.
- Davies LA, Gibson CN, Boyett MR, Hopkins PM, and Harrison SM (2000) Effects of isoflurane, sevoflurane, and halothane on myofilament Ca^{2+} sensitivity and sarcoplasmic reticulum Ca^{2+} release in rat ventricular myocytes. *Anesthesiology* **93**:1034–1044.
- Ding W, Li Z, Shen X, Martin J, King SB, Sivakumaran V, Paolucci N, and Gao WD (2011) Reversal of isoflurane-induced depression of myocardial contraction by nitroxyl via myofilament sensitization to Ca^{2+} . *J Pharmacol Exp Ther* **339**:825–831.
- Duncan JG, Ravi R, Stull LB, and Murphy AM (2005) Chronic xanthine oxidase inhibition prevents myofibrillar protein oxidation and preserves cardiac function in a transgenic mouse model of cardiomyopathy. *Am J Physiol Heart Circ Physiol* **289**:H1512–H1518.
- Fabiato A (1981) Myoplasmic free calcium concentration reached during the twitch of an intact isolated cardiac cell and during calcium-induced release of calcium from the sarcoplasmic reticulum of a skinned cardiac cell from the adult rat or rabbit ventricle. *J Gen Physiol* **78**:457–497.
- Flesch M, Schwinger RHG, Schiffer F, Frank K, Südkamp M, Kuhn-Regnier F, Arnold G, and Böhm M (1996) Evidence for functional relevance of an enhanced expression of the Na^{+} - Ca^{2+} exchanger in failing human myocardium. *Circulation* **94**:992–1002.
- Flu WJ, van Kuijk JP, Hoeks SE, Kuiper R, Schouten O, Goei D, Elhendy A, Verhagen HJ, Thomson IR, Bax JJ, et al. (2010) Prognostic implications of asymptomatic left ventricular dysfunction in patients undergoing vascular surgery. *Anesthesiology* **112**:1316–1324.
- Gao WD, Backx PH, Azan-Backx M, and Marban E (1994) Myofilament Ca^{2+} sensitivity in intact versus skinned rat ventricular muscle. *Circ Res* **74**:408–415.
- Gao WD, Liu Y, and Marban E (1996) Selective effects of oxygen free radicals on excitation-contraction coupling in ventricular muscle. Implications for the mechanism of stunned myocardium. *Circulation* **94**:2597–2604.
- Gao WD, Murray CI, Tian Y, Zhong X, DuMond JF, Shen X, Stanley BA, Foster DB, Wink DA, King SB, et al. (2012) Nitroxyl-mediated disulfide bond formation between cardiac myofilament cysteines enhances contractile function. *Circ Res* **111**:1002–1011.
- Gao WD, Perez NG, and Marban E (1998) Calcium cycling and contractile activation in intact mouse cardiac muscle. *J Physiol* **507**:175–184.
- Hammill BG, Curtis LH, Bennett-Guerrero E, O'Connor CM, Jollis JG, Schulman KA, and Hernandez AF (2008) Impact of heart failure on patients undergoing major noncardiac surgery. *Anesthesiology* **108**:559–567.
- Hasenfuss G (1998) Alterations of calcium-regulatory proteins in heart failure. *Cardiovasc Res* **37**:279–289.
- Hasenfuss G and Pieske B (2002) Calcium cycling in congestive heart failure. *J Mol Cell Cardiol* **34**:951–969.
- Hasenfuss G, Schillinger W, Lehnart SE, Preuss M, Pieske B, Maier LS, Prestle J, Minami K, and Just H (1999) Relationship between Na^{+} - Ca^{2+} -exchanger protein levels and diastolic function of failing human myocardium. *Circulation* **99**:641–648.
- Hebban L, Dorman BH, Clair MJ, Roy RC, and Spinali FG (1997) Negative and selective effects of propofol on isolated swine myocyte contractile function in pacing-induced congestive heart failure. *Anesthesiology* **86**:649–659.
- Hernandez AF, Whellan DJ, Stroud S, Sun JL, O'Connor CM, and Jollis JG (2004) Outcomes in heart failure patients after major noncardiac surgery. *J Am Coll Cardiol* **44**:1446–1453.
- Jiang Y and Julian FJ (1998) Effects of isoflurane on $[\text{Ca}^{2+}]_i$, SR Ca^{2+} content, and twitch force in intact trabeculae. *Am J Physiol* **275**:H1360–H1369.
- Joubert F, Wilding JR, Fortin D, Domergue-Dupont V, Novotova M, Ventura-Clapier R, and Veksler V (2008) Local energetic regulation of sarcoplasmic and myosin ATPase is differently impaired in rats with heart failure. *J Physiol* **586**:5181–5192.
- Juhász M, Molnár L, Fülesdi B, Végh T, Páll D, and Molnár C (2019) Effect of sevoflurane on systemic and cerebral circulation, cerebral autoregulation and CO_2 reactivity. *BMC Anesthesiol* **19**:109.
- Kanaya N, Gable B, Murray PA, and Damron DS (2003) Propofol increases phosphorylation of troponin I and myosin light chain 2 via protein kinase C activation in cardiomyocytes. *Anesthesiology* **98**:1363–1371.
- Kass DA and Solaro RJ (2006) Mechanisms and use of calcium-sensitizing agents in the failing heart. *Circulation* **113**:305–315.
- Katoh T, Suguro Y, Nakajima R, Kazama T, and Ikeda K (1992) Blood concentrations of sevoflurane and isoflurane on recovery from anaesthesia. *Br J Anaesth* **69**:259–262.
- Kawasaki S, Kiyohara C, Tokunaga S, and Hoka S (2018) Prediction of hemodynamic fluctuations after induction of general anesthesia using propofol in non-cardiac surgery: a retrospective cohort study. *BMC Anesthesiol* **18**:167.
- Kissin I, Thomson CT, and Smith LR (1983) Effect of halothane on contractile function of ischemic myocardium. *J Cardiovasc Pharmacol* **5**:438–442.
- Knott A, Purcell I, and Marston S (2002) In vitro motility analysis of thin filaments from failing and non-failing human heart: troponin from failing human hearts induces slower filament sliding and higher Ca^{2+} sensitivity. *J Mol Cell Cardiol* **34**:469–482.
- Kögler H, Hartmann O, Leineweber K, Nguyen van P, Schott P, Brodde OE, and Hasenfuss G (2003) Mechanical load-dependent regulation of gene expression in monocrotaline-induced right ventricular hypertrophy in the rat. *Circ Res* **93**:230–237.
- Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF, Sugarbaker DJ, Donaldson MC, Poss R, Ho KK, et al. (1999) Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. *Circulation* **100**:1043–1049.
- Lehnart SE, Maier LS, and Hasenfuss G (2009) Abnormalities of calcium metabolism and myocardial contractility depression in the failing heart. *Heart Fail Rev* **14**:213–224.
- LeWinter MM (2005) Functional consequences of sarcomeric protein abnormalities in failing myocardium. *Heart Fail Rev* **10**:249–257.
- Marks AR, Reiken S, and Marx SO (2002) Progression of heart failure: is protein kinase a hyperphosphorylation of the ryanodine receptor a contributing factor? *Circulation* **105**:272–275.
- Martin JL (2005) Volatile anesthetics and liver injury: a clinical update or what every anesthesiologist should know. *Can J Anaesth* **52**:125–129.
- McGlothlin D, Ivancu N, and Heerd PM (2012) Anesthesia and pulmonary hypertension. *Prog Cardiovasc Dis* **55**:199–217.
- Mebazaa A, Pitsis AA, Rudiger A, Toller W, Longrois D, Ricksten SE, Bobek I, De Hert S, Wieselthaler G, Schirmer U, et al. (2010) Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery. *Crit Care* **14**:201.
- Meng T, Bu W, Ren X, Chen X, Yu J, Eickenhoff RG, and Gao WD (2016) Molecular mechanism of anesthetic-induced depression of myocardial contraction. *FASEB J* **30**:2915–2925.
- Murphy AM and Solaro RJ (1990) Developmental difference in the stimulation of cardiac myofibrillar Mg^{2+} -ATPase activity by calmidazolium. *Pediatr Res* **28**:46–49.
- O'Rourke B, Kass DA, Tomaselli GF, Kääb S, Tunin R, and Marbán E (1999) Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure. I: experimental studies. *Circ Res* **84**:562–570.
- Pagel PS, Lowe D, Hettrick DA, Jamali IN, Kersten JR, Tessmer JP, and Warltier DC (1996) Isoflurane, but not halothane, improves indices of diastolic performance in dogs with rapid ventricular, pacing-induced cardiomyopathy. *Anesthesiology* **85**:644–654.
- Piacentino V III, Weber CR, Chen X, Weisser-Thomas J, Margulies KB, Bers DM, and Houser SR (2003) Cellular basis of abnormal calcium transients of failing human ventricular myocytes. *Circ Res* **92**:651–658.
- Poldermans D, Bax JJ, Boersma E, De Hert S, Eeckhout E, Fowkes G, Gorenek B, Hennerici MG, Iung B, Kelm M, et al.; Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery; European Society of Cardiology (ESC) (2009) Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. *Eur Heart J* **30**:2769–2812.
- Preckel B, Müllenheim J, Hoff J, Obal D, Heiderhoff M, Thämer V, and Schlack W (2004) Haemodynamic changes during halothane, sevoflurane and desflurane anaesthesia in dogs before and after the induction of severe heart failure. *Eur J Anaesthesiol* **21**:797–806.
- Rarick HM, Tu XH, Solaro RJ, and Martin AF (1997) The C terminus of cardiac troponin I is essential for full inhibitory activity and Ca^{2+} sensitivity of rat myofibrils. *J Biol Chem* **272**:26887–26892.
- Reich DL, Hossain S, Krol M, Baez B, Patel P, Bernstein A, and Bodian CA (2005) Predictors of hypotension after induction of general anesthesia. *Anesth Analg* **101**:622–628.
- Smit-Fun V and Buhre WF (2016) The patient with chronic heart failure undergoing surgery. *Curr Opin Anaesthesiol* **29**:391–396.
- Smith C, McEwan AI, Jhaveri R, Wilkinson M, Goodman D, Smith LR, Canada AT, and Glass PS (1994) The interaction of fentanyl on the Cp50 of propofol for loss of consciousness and skin incision. *Anesthesiology* **81**:820–828; discussion 26A.
- Sprung J, Ogletree-Hughes ML, McConnell BK, Zakhary DR, Smolsky SM, and Moravec CS (2001) The effects of propofol on the contractility of failing and nonfailing human heart muscles. *Anesth Analg* **93**:550–559.
- Stones R, Benoist D, Peckham M, and White E (2013) Microtubule proliferation in right ventricular myocytes of rats with monocrotaline-induced pulmonary hypertension. *J Mol Cell Cardiol* **56**:91–96.
- Stull LB, Leppo MK, Szweda L, Gao WD, and Marbán E (2004) Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. *Circ Res* **95**:1005–1011.
- Tan Z, Dai T, Zhong X, Tian Y, Leppo MK, and Gao WD (2009) Preservation of cardiac contractility after long-term therapy with oxypurinol in post-ischemic heart failure in mice. *Eur J Pharmacol* **621**:71–77.
- van der Velden J (2011) Diastolic myofilament dysfunction in the failing human heart. *Pflugers Arch* **462**:155–163.
- van der Velden J, Papp Z, Boontje NM, Zaremba R, de Jong JW, Janssen PM, Hasenfuss G, and Stienen GJ (2003) The effect of myosin light chain 2 dephosphorylation on Ca^{2+} -sensitivity of force is enhanced in failing human hearts. *Cardiovasc Res* **57**:505–514.
- Vivien B, Hanouz JL, Gueugniaud PY, Lecarpentier Y, Coriat P, and Riou B (1997) Myocardial effects of halothane and isoflurane in hamsters with hypertrophic cardiomyopathy. *Anesthesiology* **87**:1406–1416.
- Vivien B, Lecarpentier Y, Riou B, and Coirault C (2005) Halothane and isoflurane do not directly interact with cardiac cross-bridge function. *Anesthesiology* **102**:364–370.
- Yuan C, Guo Y, Ravi R, Przyklenk K, Shilkofski N, Diez R, Cole RN, and Murphy AM (2006) Myosin binding protein C is differentially phosphorylated upon myocardial stunning in canine and rat hearts-- evidence for novel phosphorylation sites. *Proteomics* **6**:4176–4186.

Address correspondence to: Dr. Wei Dong Gao, Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins University School of Medicine, Zayed 6208, 1800 Orleans Street, Baltimore, MD 21287. E-mail: wgao3@jhmi.edu